Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The burden of skin and soft tissue, bone and joint infections in an Australian cohort of people who inject drugs.

BMC infectious diseases·2024
Same author

Renal medicine in the intensive care unit: a narrative review.

Anaesthesia·2023
Same author

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.

HIV medicine·2020
Same author

Cardiovascular disease and diabetes in HIV-positive and HIV-negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study.

HIV medicine·2018
Same author

Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.

HIV medicine·2017
Same author

Low rates of endocarditis in healthcare-associated Staphylococcus aureus bacteremia suggest that echocardiography might not always be required.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2015

Related Experiment Video

Updated: May 18, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Shooting at the DARC: potential issues with species-specific antimalarials.

I Woolley1, K Horne

  • 1Department of Infectious Diseases, Monash Medical Centre, Monash University, Clayton, Victoria, Australia. ian.woolley@monash.edu

Infectious Disorders Drug Targets
|September 29, 2012
PubMed
Summary

Novel drug design offers targeted malaria treatment by blocking cellular entry. CCR5 blockers, used for HIV, show potential against Plasmodium vivax malaria by inhibiting red blood cell invasion, possibly reducing drug resistance.

More Related Videos

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

Related Experiment Videos

Last Updated: May 18, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
05:28

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

Area of Science:

  • Malariology and Drug Discovery
  • Infectious Disease Research
  • Medicinal Chemistry

Background:

  • Malaria treatment faces challenges with drug resistance and species-specific infections.
  • Targeting pathogen cellular entry is a key strategy for novel therapeutic development.
  • Existing drugs may be repurposed for new indications, offering potential benefits.

Purpose of the Study:

  • To explore the potential of novel drug design in malaria treatment.
  • To discuss the risks and benefits of targeting pathogen cellular entry mechanisms.
  • To evaluate CCR5 blockers as potential agents against Plasmodium vivax malaria.

Main Methods:

  • Review of scientific literature on drug design and malaria.
  • Analysis of cellular entry pathways for malaria parasites.
  • Examination of CCR5 blockers and their potential interaction with DARC receptors.

Main Results:

  • Novel agents can be designed for species-specific malaria targeting.
  • CCR5 blockers, used in HIV treatment, may inhibit Plasmodium vivax entry via DARC.
  • Potential benefits include reduced development of Plasmodium falciparum resistance.

Conclusions:

  • Targeted drug design offers a promising avenue for malaria control.
  • Repurposing existing drugs like CCR5 blockers warrants further investigation for malaria therapy.
  • Understanding cellular entry mechanisms is crucial for developing effective anti-malarial strategies.